Emergency medical service/airway/brief research reportEtomidate Versus Midazolam for Out-of-Hospital Intubation: A Prospective, Randomized Trial
Introduction
Sedation-facilitated intubation without paralytics is used by many emergency medical services (EMS) despite limited data to support the practice. The American College of Emergency Physicians’ recent policy statement on drug-assisted intubation in the out-of-hospital setting states that the practice of drug-assisted intubation “is an advanced airway procedure that should not be considered mandatory” for out-of-hospital EMS systems but is ambiguous about sedative-facilitated intubation (without paralytics), recommending that an out-of-hospital drug-assisted intubation program include “standardized drug-assisted intubation protocols, including the use of sedation and neuromuscular blockade.”1 At least 1 report noted limited success with etomidate-only assisted intubation,2 a provocative finding because etomidate is arguably safer than midazolam.3, 4 To our knowledge, this is the first study to compare the utility of etomidate and midazolam for sedative-facilitated intubation in a randomized, controlled, out-of-hospital trial.
Although retrospective series2, 5, 6, 7, 8 have compared etomidate and midazolam for out-of-hospital intubation, there have been no direct comparisons of the 2 drugs. Previous studies have suggested that to be as effective as etomidate for intubation, the doses of midazolam that must be used are more likely than etomidate to cause hypotension.3, 4 Because sedative-facilitated intubation is used by many out-of-hospital services5, 6, 7, 8 and is included as a component of the most recent published algorithm for out-of-hospital intubation,9 the question of which drug is most effective (has the highest success rate for intubation) and safest (has the least propensity to cause adverse effects) is of considerable importance.
The primary objective of this study was to compare the success rate of etomidate and midazolam for sedative-facilitated intubation in out-of-hospital adult patients. The secondary objectives were to compare the safety and perceived difficulty of intubation with the 2 drug regimens.
Section snippets
Study Design
The study began in October 2002 and continued for 32 months, until June 2005. The hospital pharmacy prepared numbered syringes (assigned by a random number table), each containing either 7 mg of midazolam (0.1 mg/kg × 70 kg) or 20 mg of etomidate (0.3 mg/kg × 70 kg). To further ensure blinding, the midazolam was mixed with normal saline solution to a volume equivalent to that in the etomidate syringe, and the syringe contents were concealed with labels such that only the syringe number was
Results
There were 115 patients entered into the study, and 110 completed it; 55 patients received midazolam and 55 patients were given etomidate. Five patients were excluded: 3 because of confusion about syringe numbers and data forms, which made it impossible to be certain what drug was administered (2 were successful); 1 because the intubation was attempted by an out-of-hospital physician rather than a medic (failed); and 1 because the patient woke up with naloxone before intubation was attempted.
Limitations
One limitation of our study is related to our regimen of drug dosing. First, by specifying a fixed dosage for both agents (7 mg of midazolam, 20 mg of etomidate), the effectiveness of 1 or both drugs might be suboptimal, and the adverse effect profile might be inaccurate as well. Moreover, the performance characteristics of any dosage regimen, even one that is weight based, could vary markedly, depending on the dosages used. Conversely, our data provide some evidence that in the case of
Discussion
This study, which directly compares the utility of etomidate and midazolam for sedative-facilitated intubation, demonstrates no important clinical differences between etomidate and midazolam used in the out-of-hospital setting for sedative-facilitated intubation. Our intubation success rate of 76% is low compared with the high success rates sometimes reported in the out-of-hospital sector, particularly when rapid sequence intubation is used, but is consistent with other series of
References (13)
- et al.
Regional EMS experience with etomidate for facilitated intubation
Prehosp Emerg Care
(2002) - et al.
The use of midazolam for prehospital rapid-sequence intubation may be associated with a dose-related increase in hypotension
Prehosp Emerg Care
(2001) - et al.
The utilization of midazolam as a pharmacologic adjunct to endotracheal intubation by paramedics
Prehosp Emerg Care
(2000) - et al.
Comparison of etomidate and midazolam for prehospital rapid-sequence intubation
Prehosp Emerg Care
(2004) American College of Emergency Physicians Policy Statement. Drug-assisted intubation in the prehospital setting
Ann Emerg Med
(2005)- et al.
Midazolam is more likely to cause hypotension than etomidate in emergency department rapid sequence intubation
Emerg Med J
(2004)
Cited by (47)
Current practices and safety of medication use during rapid sequence intubation
2018, Journal of Critical CareCitation Excerpt :Despite these risks we found they were used in 14% and 20% of patients, respectively. The calculated doses used based on ABW were much lower than recommended in drug information references (midazolam 0.1–0.3 mg/kg and propofol 2–2.5 mg/kg), but lower doses more often used in the critically ill population have been shown to produce similar intubating conditions to etomidate [6–8]. Both propofol and ketamine are recommended to be dosed based on IBW.
Sedation and analgesia in emergency structure. Which sedation and/or analgesia for tracheal intubation?
2012, Annales Francaises d'Anesthesie et de ReanimationPrehospital Airway Management in Severe Traumatic Brain Injury
2019, Air Medical JournalCitation Excerpt :Therefore, ketamine is now considered a safe drug in the prehospital setting, and its use is widely spread, in particular in hemodynamically unstable patients.24 Etomidate is widely used in the prehospital setting, and it appears to grant intubating conditions and hemodynamic stability similar to midazolam.25,26 However, its use in critically ill patients, especially septic patients, has been challenged because of the possible induction of reversible adrenal insufficiency.27
Etomidate for emergency airway management: The basis of the controversy
2018, Acta Colombiana de Cuidado Intensivo
Supervising editor: Donald M. Yealy, MD
Author contributions: JJ, MH, JN conceived the study and designed the trial. JJ, GS, JM supervised the conduct of the trial and data collection. JR provided statistical advice on study design and analyzed the data and performed interim analysis. MC, JJ, GS, JN were responsible for paramedic teaching and field implementation. NP performed data collection and formatting (pre-hospital). SJ performed data collection and formatting (follow-up). JJ and MH drafted the manuscript. JJ takes responsibility for the paper as a whole.
Funding and support: The authors report this study did not receive any outside funding or support.
Reprints not available from the authors.